Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type

Br J Haematol. 2019 Nov;187(3):e79-e82. doi: 10.1111/bjh.16211. Epub 2019 Sep 30.

Authors

Cosimo Di Raimondo^{1

2}, Farah R Abdulla¹, Jasmine Zain³, Christiane Querfeld^{1

3

4}, Steven T Rosen^{3

4}

Affiliations

¹ Division of Dermatology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
² Department of Dermatology, Policlinico "Tor Vergata", Rome, Italy.
³ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
⁴ Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

PMID: 31566707
DOI: 10.1111/bjh.16211

No abstract available

Keywords: drug antibodies; drug resistance; haematological malignancies; immunotherapy.

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Leg / pathology
Lenalidomide / administration & dosage*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / pathology
Male
Rituximab / administration & dosage*
Salvage Therapy / methods
Skin Neoplasms / pathology

Substances

Antibodies, Monoclonal, Humanized
Rituximab
pembrolizumab
Lenalidomide